Register Now: Advancing AI Adoption in Manufacturing Under the Existing FDA & EMA Frameworks

Date: March 11, 2026
Time: 10-11am ET
Registration link: https://comms.arnoldporter.com/64/6809/landing-pages/accept–blank-.asp?sid=600d0e23-07f6-4967-9925-756d145366f1 

Artificial intelligence is quickly becoming a powerful tool across pharmaceutical and biotechnology manufacturing. Yet many organizations remain uncertain about how to adopt AI within regulated environments, particularly in the absence of AI-specific regulations.

In reality, existing regulatory frameworks already provide the structure needed to support AI-enabled approaches within current good manufacturing practices (cGMP). The key is understanding how to apply those frameworks effectively while maintaining compliance, oversight, and quality.

Join Lachman Consultants and Arnold & Porter for an upcoming webinar exploring how organizations can move forward with AI adoption using today’s regulatory expectations.

Advancing AI Adoption in Manufacturing Under the Existing FDA & EMA Frameworks will examine how regulators are approaching AI within pharmaceutical manufacturing and how companies can align innovation with established GMP principles.

Our panel of experts will discuss how existing regulatory frameworks, including FDA and EMA expectations, can support responsible AI implementation across the product lifecycle, with particular focus on manufacturing applications.

Webinar Speakers

Howard Sklamberg, Partner — Arnold & Porter
Alexander Roussanov, Partner — Arnold & Porter
Elizabeth Trentacost, Senior Associate — Arnold & Porter
Scott Deckebach, Executive Director — Lachman Consultants
Joe Pham, Director, Compliance Practice — Lachman Consultants
April Inyard Alexandrow, Program Manager — Lachman Consultants

Whether your organization is actively exploring AI or evaluating how it may fit within your manufacturing operations, this session will provide valuable perspective from regulatory and industry experts.

Register to learn how companies can responsibly advance AI adoption while operating within existing FDA and EMA regulatory frameworks.